On February 25, 2020, the Securities and Exchange Commission ("SEC") announced that Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a biopharmaceutical company based in Brittany, France, has agreed to pay $75 million to settle charges that it is developing a novel, kinase inhibitor for atopic dermatitis.  According to the SEC's complaint, filed in the U.S. District Court for the Southern District of New York, ATI-450 was developed with the assistance of Lisa Monahan, Dorothy Changelian, Jon Juliasen and Theresa Smith, and was developed with the assistance of a later stage development team based in Brittany.  The complaint alleges that ATI-450 was not associated with any meaningful food effect or drug-drug interaction with methotrexate.  The complaint further alleges that ATI-450 was not associated with a meaningful food effect or drug-drug interaction with Methotrexate.  The SEC's complaint, filed in the SEC's Eastern District of New York, alleges that ATI-450 violated Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, Aclaris has agreed to settle the SEC's charges without admitting or denying the allegations in the complaint.  The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Jennifer Smith and Carol Frost and supervised by Scott Frost.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York and the Federal Bureau of Investigation.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.